24 results about "Protein subunit" patented technology

The invention relates to the field of antibody proteins, in particular to an immunoglobulin Fc dimer with a stable disulfide bond, an Fc fusion protein containing the Fc protein dimer and a calculation design method of the Fc fusion protein. The immunoglobulin Fc protein dimer comprises two protein subunits, a CH3 structural domain of each subunit contains at least one cysteine mutation, and the two protein subunits are combined through an interchain disulfide bond formed by mutation cysteine. Cysteine mutation is specifically introduced into the CH3 structural domain of the Fc region of the immunoglobulin to form a stable interchain disulfide bond, so that the problem of insufficient stability of the Fc protein dimer is solved.

The application relates to preparation and application of a giant Eimeria nanosubunit vaccine. The nanosubunit vaccine PLGA-rEmLPL is prepared by coating E. maxima Treg-induced molecule EmLPL recombinant protein (rEmLPL) with PLGA nanoparticles. The immunoprotective effects of the subunit vaccine rEmLPL and the nanosubunit vaccine PLGA-rEmLPL are evaluated through animal immunoprotection tests, and the results show that both the vaccines can produce good immunoprotective effects on E. maxima infection. After the recombinant protein subunit vaccine rEmLPL is coated with the PLGA nanoparticles, the immunoprotective effect of the nanosubunit vaccine PLGA-rEmLPL on animals is improved compared with that of the subunit vaccine rEmLPL.

Methods of treating preventing and / or substantially reducing a Pseudomonas aeruginosa (PA) infection and / or a Staphylococcus aureus (SA) infection by administration of a bivalent protein subunit-based vaccine are described. The vaccine can protect subjects with a prior history of exposure to SA from a new exposure to PA or SA, including methicillin resistant SA (MRSA), as well as being able to protecting with no prior exposure to a SA infection. Vaccine formulations are also described.

The present disclosure generally relates to cancer therapies and, in some embodiments, to using genetic circuits designed for targeted cancer therapies. The genetic circuit, in some embodiments, utilizes a suitable vector capable of delivering DNA sequences comprising functional units comprising a transcriptional promoter, target sequences and a transcriptional terminator. Together, the genetic circuit, in some embodiments, may trigger apoptosis — a target protein activity where cell death occurs — in cancer cells, and protect non-cancer cells from apoptosis. In some embodiments, the genetic circuit may direct target protein activity in cancer cells, while not directing protein activity in non-cancer cells. However, in the presence of certain stimuli, the inhibition is relieved, which may lead to the induction of target protein activity in cancer cells. In addition, some embodiments are generally directed to vectors comprising a first sequence encoding at least a portion of Mdm2 and a promoter, and a second sequence encoding a promoter and a fusion protein comprising at least a portion of p53 and iCasp-9 (or another protein capable of achieving a therapeutic objective), optionally connected by a linker sequence capable of allowing each protein subunit of the fusion protein to be independently active but subject to the same proteolytic pathways as p53 in cancer and non-cancer cells. Other aspects are generally directed to methods of making or using such compositions, kits including such compositions, or the like.

This application belongs to the field of nanomedicine technology, and particularly relates to an artificially evolved protein cage nanomedicine, its preparation method, and its application. The artificially evolved protein cage nanomedicine provided by this application includes an artificially evolved protein cage and a nucleic acid-based biomolecular drug. The artificially evolved protein cage is artificially obtained by an artificial evolution system from a 240-polymer nanoprotein cage C27-A with PDB number 6NJ8. The amino acid sequence of the protein subunit of the artificially evolved protein cage is shown in SEQ ID NO.1. The artificially evolved protein cage can efficiently encapsulate nucleic acid-based biomolecular drugs and has advantages such as high protein yield, good stability, good tumor efficacy, and excellent safety. It can solve the technical problem of low drug encapsulation efficiency in existing protein cage nanomedicines.

This invention relates to the field of pharmaceutical technology, and more particularly to fusion proteins of human heavy chain ferritin or its variants with polyhedral or granular proteins and their applications. This invention fuses a ferritin variant with a baculovirus polyhedral protein subunit to obtain particles with a diameter <20 nm, consisting of a polyhedral protein outer layer and a ferritin inner layer. The particles have an outer diameter of 17 nm, an inner lumen of 13 nm, and are positively charged. pH adjustment enables the depolymerization and recombination of the outer and inner layers, allowing the encapsulation of negatively charged insulin molecules with a diameter >8 nm. Proteins fused with polyhedral or granular protein subunits to wild-type or mutant ferritin can self-assemble into bilayer nanoparticles. The inner layer is a cage-like structure with a positive or negatively charged lumen and a size of 8 nm or 13 nm; the outer layer is a polyhedral or granular protein layer, exhibiting resilience, resistant to high temperatures and dehydration, and resistant to digestion by pepsin and trypsin. These nanoparticles can serve as oral carriers for various active molecules.

Provided are methods of producing an isolate of soluble proteins from moringa leaves, and methods of preparing a powder of soluble proteins from moringa leaves. Also provided are compositions-of-matter comprising a chlorophyll-free preparation of soluble proteins of moringa leaves, wherein the soluble proteins comprise large and small Rubisco protein subunits, a preparation comprising the composition-of-matter, and edible, cosmetic and pharmaceutical compositions comprising same.

The invention relates to a formate dehydrogenase mutant and application thereof, and belongs to the field of enzyme engineering and carbon dioxide reduction. The invention provides a formate dehydrogenase mutant. The formate dehydrogenase mutant comprises a formate dehydrogenase catalytic subunit FdhA, an electron transport subunit FdhB and a membrane anchoring protein subunit FdhC, compared with formate dehydrogenase, the formate dehydrogenase mutant has the advantages that a membrane anchor protein subunit FdhC is deleted, or the membrane anchor protein subunit FdhC and an electron transport subunit FdhB are deleted. Compared with the existing formate dehydrogenase, the formate dehydrogenase mutant provided by the invention has high activity and can tolerate oxygen at the same time. The formate dehydrogenase mutant provided by the invention shows huge potential value in the carbon dioxide immobilization industry.

The application belongs to the technical field of biological medicine, and discloses a recombinant protein subunit vaccine constructed by combining Salmonella flagellin and a COE region of porcine epidemic diarrhea virus (PEDV). The application specifically discloses a fusion protein, wherein the fusion protein comprises Salmonella flagellin FliC L3A a mutant and a PEDV structural protein connected to the C terminal of the Salmonella flagellin FliC L3A The subunit vaccine obtained by emulsifying the fusion protein and the adjuvant can effectively prevent the G2b subfamily of PEDV, initiate a downstream immune response, induce a series of immune responses of the body, make the mucosal immune system of the body produce a large number of PEDV-specific antibodies to resist the invasion of external pathogens, and has the effect of specific immune protection.

The application discloses a protein subunit vaccine adjuvant for pathogenic bacteria of Pelteobagrus fulvidraco, a preparation method and application, wherein the protein subunit vaccine adjuvant is encoded by a nucleic acid sequence, the nucleic acid sequence comprises SEQ ID NO. 1, the encoded protein of the nucleic acid sequence is the protein subunit vaccine adjuvant, and the protein subunit vaccine adjuvant comprises amino acids shown as SEQ ID NO. 2. The protein subunit vaccine adjuvant is an IL6 protein of the Pelteobagrus fulvidraco, can be used as a vaccine adjuvant, significantly improves the immune effect of a vaccine for the Pelteobagrus fulvidraco, and specifically shows that serum lysozyme activity and complement C3 content are improved, immune-related genes (such as IL-1β and TNF-α) are enhanced in expression, and the protection rate of the vaccine after an attack of Edwardsiellaictaluri is significantly improved. The application further discloses a combined immunization composition composed of the IL6 protein and the OmpC protein of the Edwardsiellaictaluri and application of the combined immunization composition in preparation of an Edwardsiellaictaluri subunit vaccine.

This invention provides a composition and method for genomic modification of target sequences in the cellular genome using a novel Cas endonuclease. [Solution] An effective system is provided for modifying or altering target sequences in the genome of a cell or organism using a guide polynucleotide / endonuclease system. Also provided are novel effectors and endonuclease systems, such as guide polynucleotide / endonuclease systems containing endonucleases, and elements containing such systems. Furthermore, compositions and methods are provided for guide polynucleotide / endonuclease systems comprising at least one endonuclease optionally covalently or noncovalently linked to or assembled with at least one further protein subunit.

Provided are a virus peptide-protein subunit combination vaccine based on DNA nanotechnology, and a preparation method therefor and use thereof, which belong to the technical field of biological products. Provided is a virus peptide-protein subunit combination vaccine based on DNA nanotechnology, in which a tetrahedral framework nucleic acid formed by assembly of DNA strands is used as a vector, a protein antigen triggering virus-specific T cell activation is coupled to one edge of the tetrahedral framework nucleic acid, and B cell epitope peptides of a virus are coupled to four vertices of the tetrahedral framework nucleic acid.

The application relates to preparation and application of a nano-subunit vaccine for preventing chicken coccidiosis. The nano-subunit vaccine PLGA-rEmTregIM-1 is prepared by coating a giant Eimeria maxima Treg inducing molecule EmTregIM-1 recombinant protein (rEmTregIM-1) with PLGA nanoparticles. The immunoprotective effects of the subunit vaccine rEmTregIM-1 and the nano-subunit vaccine PLGA-rEmTregIM-1 are evaluated through animal immunoprotection tests, and the results show that both the vaccines can produce partial immunoprotections for the giant Eimeria maxima infection. After the recombinant protein subunit vaccine rEmTregIM-1 is coated with the PLGA nanoparticles, the nano-subunit vaccine PLGA-rEmTregIM-1 has an improved immunoprotection effect on animals compared with the subunit vaccine rEmTregIM-1.

The invention discloses a canine anti-cystic hydatid double-antigen recombinant protein subunit vaccine and a preparation method thereof, and relates to the technical field of biological medicines. The canine anti-cystic hydatid double-antigen recombinant protein subunit vaccine takes recombinant proteins rEg 05752 and rEg 09809 as core double antigens, and the recombinant proteins rEg 05752 and rEg 09809 do not have transmembrane regions and signal peptides and contain a plurality of B cell antigen epitopes. After a beagle is immunized, a body can be efficiently induced to generate a specific IgG antibody, the titer of the antibody reaches a peak value 35 days after immunization and still maintains a relatively high level after attack, and meanwhile, Th1 / Th2 type mixed immune response is remarkably activated, so that the levels of cell factors such as IL-2, IFN-gamma, IL-4 and IL-5 are greatly improved. The immune protection effect is remarkable, and a safe and efficient novel technical means is provided for source prevention and control of the cystic echinococcosis.

The invention discloses a protein subunit vaccine adjuvant aiming at pathogenic bacteria of pelteobagrus fulvidraco, a preparation method and application, the protein subunit vaccine adjuvant is coded by a nucleotide sequence, the nucleotide sequence is shown as SEQ ID NO.1, the protein coded by the nucleotide sequence is the protein subunit vaccine adjuvant, and the protein subunit vaccine adjuvant is a protein subunit vaccine adjuvant. The protein subunit vaccine adjuvant comprises an amino acid as shown in SEQ ID NO. 2. The protein subunit vaccine adjuvant is pelteobagrus fulvidraco IL6 protein and can be used as a vaccine adjuvant, the immune effect of a pelteobagrus fulvidraco vaccine is remarkably improved, specifically, the activity of lysozyme in serum and the content of complement C3 are improved, the expression of immune-related genes (such as IL-1beta and TNF-alpha) is enhanced, and the protection rate of the vaccine on edwardsiella ictaluri after toxin attacking is remarkably increased. The invention further discloses a combined immune composition composed of the IL6 protein and the edwardsiella ictaluri OmpC protein, and application of the combined immune composition in preparation of edwardsiella ictaluri subunit vaccines.

The present disclosure relates to fusion proteins comprising a mutant IL-2 polypeptide subunit and one or two antigen binding domains (e.g., VHH antibodies) that specifically bind to an antigen expressed on the surface of immune cells such as tumor reactive T cells expressing CD8 and / or PD1. The fusion can also comprise a half-life extending protein subunit such as an Ig1 Fc region monomer polypeptide. The present disclosure also relates to the use of these fusion proteins as therapeutic agents, for example, in pharmaceutical compositions for treating cancer and autoimmune disorders.

The application belongs to the technical field of nano drugs, and particularly relates to a protein cage nano drug with a slow-release effect and a preparation method and application thereof. The protein cage nano drug with the slow-release effect is provided in the application, a protein binding peptide is modified at a C end of a protein subunit monomer of a nano protein cage, and is combined with a protein with a long half-life in a body, so that a drug action time is prolonged, a drug efficacy is improved, and a possible drug toxic side effect is weakened. Meanwhile, the protein binding peptide is selected from a serum albumin binding peptide with an amino acid sequence as shown in SEQ ID NO. 1, so that the protein cage nano drug provided in the technical solution can be combined with the most abundant endogenous protein in blood, and the half-life of the high-concentration protein cage nano drug can also be prolonged. The technical problem that there is a lack of slow-release protein cage nano drugs and it is difficult to release drugs for a long time in the prior art is solved.

The application provides a fusion protein based on VP8-Fc, and a rotavirus protein subunit vaccine and an mRNA vaccine constructed by taking the fusion protein as a core. Animal experiment results show that, whether the protein subunit vaccine or the mRNA vaccine, after immunization, the mice can produce strong humoral immune response, and show excellent immunogenicity and potential cross-protection capacity. Through fusion design of the rotavirus VP8 structure domain and the Fc fragment, the application provides a novel rotavirus vaccine capable of inducing broad-spectrum and strong immune response.

This invention belongs to the field of genetic engineering vaccine technology, specifically relating to a subunit vaccine against *Avibacterium avium* (type A) in chickens, its preparation method, and its application. The subunit vaccine comprises the OMA87 protein, with a size of 97.15 kDa, the gene sequence of which is shown in SEQ.ID.NO.4, and the amino acid sequence in SEQ.ID.NO.5. After induction of expression, the OMA87 protein was purified and detoxified to obtain a semi-finished antigen with a purity of over 50% and an endotoxin content below 2500 EU / mL. Using white oil adjuvant, a qualified OMA87 protein subunit vaccine was prepared through emulsification, thus becoming the *Avibacterium avium* subunit vaccine. This vaccine demonstrates good safety in broilers and laying hens, producing high and long-lasting antibody levels, providing a method for preventing *Avibacterium avium* infection in broilers and laying hens.

This invention belongs to the field of biotechnology, specifically relating to a method and application for the isolation and preparation of detached spike protein S1 subunits. This invention successfully isolates detached S1 protein subunits using PEG precipitation, a rapid, convenient, and reliable method that yields structurally correct and stable S1 units. By simulating the binding of the spike protein to ACE2 during coronavirus infection, the S1 subunit is detached. The tag carried by the S1 subunit is then used to isolate and purify the naturally detached S1 subunit, resulting in structurally correct and stable S1 units. The S1 subunit protein is a core functional unit for viral invasion; drug design based on its naturally detached structure can efficiently inhibit viral fusion and is an important target for screening blocking agents (such as small molecules, antibodies, and nucleic acid aptamers). The detached S1 subunit retains an intact antigenic epitope and can be used as a core reagent in detection methods such as ELISA, immunochromatography, and biosensors for detecting viruses or neutralizing antibodies.

Compositions, methods, and systems are provided for genome modification of a target sequence in the genome of a cell, using novel engineered Cas endonucleases. These can include a guide polynucleotide / endonuclease system to modify or alter target sequences in the genome of a cell or organism. Also provided are novel effectors and endonuclease systems and elements comprising such systems. Compositions, methods, and systems are also provided that include a guide polynucleotide / endonuclease system comprising at least one endonuclease, optionally covalently or non-covalently linked to, or assembled with, at least one additional protein subunit or substrate.

The application discloses an epidermal growth factor receptor pathogenicity prediction method and device, a server and a medium, comprising: extracting the three-dimensional space conformation amino acid residue characteristics of the composite mutation amino acid sequence, and generating an initial amino acid residue structure graph; predicting by using a first graph neural network, and generating a second-level amino acid cluster structure graph by weighted aggregation; predicting by using a second graph neural network, and generating a higher-level protein subunit structure graph by weighted aggregation; predicting by using a third graph neural network, and then performing feature mapping to obtain a protein structure feature vector for pathogenicity evaluation of a mutation site. Compared with the prior art, the application adopts a layer-by-layer deep graph neural network architecture, accurately captures the comprehensive influence of multiple mutation sites on a multi-level protein structure, thereby effectively evaluating the pathogenicity of an epidermal growth factor receptor mutation site, and improving the accuracy and comprehensiveness of prediction.

The present invention provides a chimeric protein subunit comprising, linked to each other, (a) a D12 subunit of an RNA capping enzyme or a functional fragment thereof, or a variant having at least 90% sequence identity thereto and having the activity of a D12 subunit, and (b) an RNA cap structure 2'-O-methyltransferase or a functional fragment thereof, or a variant having at least 90% sequence identity thereto and having the activity of an RNA cap structure 2'-O-methyltransferase. The present invention also provides a chimeric protein comprising said chimeric protein subunit and a D1 subunit of an RNA capping enzyme or a functional fragment thereof.

A method for producing a SARS-CoV-2 virus-like particle-based protein subunit vaccine. The method comprises creating a fusion protein by combining a DNA sequence encoding an iLOV protein with a DNA se